Skip to main
BLFS
BLFS logo

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. demonstrated robust financial performance, with Cell Processing revenue reaching $23 million, reflecting a 28% year-over-year increase and a 6% quarter-over-quarter growth. Additionally, the company raised its 2025 revenue guidance to $100-103 million, indicating anticipated overall growth of 22-25% year-over-year, driven largely by the strong performance in Cell Processing. Furthermore, management has indicated a projected reduction in net loss and an expansion of adjusted EBITDA margin, underscoring the potential for continued growth and improved profitability.

Bears say

BioLife Solutions Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from lower than projected growth in its product and service offerings. The company's recent financial performance indicated a net loss of $15.8 million, or ($0.33) per share, which was substantially higher than anticipated due to considerable expenses linked to ongoing research and development, particularly related to the PanTHERA transaction. Additionally, risks surrounding customer acquisition, fluctuating sales in emerging markets, foreign exchange volatility, and potential dilution further exacerbate the uncertainties affecting the company's financial stability and growth prospects.

BioLife Solutions (BLFS) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Buy based on their latest research and market trends.

According to 4 analysts, BioLife Solutions (BLFS) has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.